FLUDEOXYGLUCOSE (F-18) SOLUTION

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

FLUDEOXYGLUCOSE 18F

Sẵn có từ:

LAWSON HEALTH RESEARCH INSTITUTE

Mã ATC:

V09IX04

INN (Tên quốc tế):

FLUDEOXYGLUCOSE (18F)

Liều dùng:

232GBQ

Dạng dược phẩm:

SOLUTION

Thành phần:

FLUDEOXYGLUCOSE 18F 232GBQ

Tuyến hành chính:

INTRAVENOUS

Các đơn vị trong gói:

20ML

Loại thuốc theo toa:

Schedule C

Khu trị liệu:

ROENTGENOGRAPHY

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0152591014; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2018-10-02

Đặc tính sản phẩm

Fludeoxyglucose (
18
F)
1
PRODUCT MONOGRAPH
TRADE NAME
Fludeoxyglucose (
18
F) Injection
0.5 to 232 GBq/vial
Diagnostic Radiopharmaceutical
Lawson Health Research Institute
268 Grosvenor Street
London ON N6A 4V2
Date of Approval:
March 9, 2017
Control #:
197018
Fludeoxyglucose (
18
F)
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
DESCRIPTION
...............................................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
4
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
5
ADVERSE REACTIONS
...............................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
6
DOSAGE AND ADMINISTRATION
...........................................................................................
7
RADIATION DOSIMETRY
..........................................................................................................
9
OVERDOSAGE............................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
11
STORAGE AND STABILITY
.....................................................................................................
12
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
12
DOSAGE FORM